PMID: 6159711Jun 1, 1980Paper

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study

Tubercle

Abstract

Four short-course chemotherapy regimens for pulmonary tuberculosis have been compared: (1) streptomycin, isoniazid, rifampicin and pyrazinamide daily for 2 months followed by daily thiacetazone plus isoniazid; (2) the same 4 drugs daily for 1 month followed by thiacetazone plus isoniazid; (3) the same 4 drugs daily for 1 month followed by twice-weekly streptomycin, isoniazid and pyrazinamide; (4) the first regimen but without pyrazinamide in the initial intensive phase. Each regimen was given for 6 and 8 months and patients were followed up to 30 months. When given for 6 months the regimen with a 2-month 4-drug intensive phase had a bacteriological relapse rate of 13% and when given for 8 months there were no relapses. When pyrazinamide was omitted in the first 2 months the relapse rates were 18% for the 6-month and 6% for the 8-month series. The regimen with the 4-drug initial phase shortened to 1 month had relapse rates of 18% and 7% respectively if the continuation phase was thiacetazone plus isoniazid. However, the relapse rates were lower, 9% and 2% respectively, when the continuation phase was twice-weekly streptomycin, isoniazid and pyrazinamide.

Citations

Nov 1, 1980·Lancet·D J GirlingD A Mitchison
Jun 28, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eline L KorenrompPaul Nunn
Aug 31, 2007·The Journal of Infectious Diseases·Philip Chukwuka OnyebujohChristopher Curtis Whalen
Apr 10, 1999·AIDS·A L PozniakL P Ormerod
Jan 10, 2003·American Journal of Respiratory and Critical Care Medicine·Amina JindaniDenis A Mitchison
Apr 19, 2003·American Journal of Respiratory and Critical Care Medicine·John L JohnsonUNKNOWN Uganda-Case Western Reserve University Research Collaboration
Sep 18, 2004·American Journal of Respiratory and Critical Care Medicine·Kwok C ChangCheuk M Tam
May 6, 2006·American Journal of Respiratory and Critical Care Medicine·William J BurmanRichard E Chaisson
Aug 16, 2006·American Journal of Respiratory and Critical Care Medicine·Kwok C ChangCheuk M Tam
May 2, 2009·American Journal of Respiratory and Critical Care Medicine·Susan E DormanUNKNOWN Tuberculosis Trials Consortium
Jun 23, 2009·American Journal of Respiratory and Critical Care Medicine·John L JohnsonW Henry Boom
May 23, 2014·Drugs·Abdullah Alsultan, Charles A Peloquin
May 15, 2012·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·S Rajasekaran, Gaurav Khandelwal
Feb 18, 2003·American Journal of Respiratory and Critical Care Medicine·Henry M BlumbergUNKNOWN American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society
Jun 28, 2005·American Journal of Respiratory and Critical Care Medicine·Robert S Wallis
Nov 2, 2015·Advances in Medical Sciences·Moses NjireTianyu Zhang
Feb 28, 2009·The Lancet Infectious Diseases·Robert S WallisAlimuddin Zumla
Jun 1, 1987·Tubercle·T Shimao
Oct 1, 1981·British Journal of Diseases of the Chest·W Fox
Jul 1, 1987·British Journal of Diseases of the Chest·L P Ormerod, N Horsfield
Nov 30, 2004·Lancet·Amir Attaran
Feb 1, 1996·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A M Elliott, S D Foster
Jul 29, 2003·Expert Opinion on Investigational Drugs·Peter D O Davies, W W Yew
Nov 23, 2006·Respiratory Medicine·Cesare Saltini
Jan 1, 1986·International Quarterly of Community Health Education·R L LaborinJ P Elder
Nov 9, 2007·PLoS Medicine·Neil SchlugerRichard Chaisson
Jun 29, 2016·Pharmaceutical Research·E F YoungAnthony J Hickey
Apr 13, 2010·Tuberculosis·D A Mitchison, P B Fourie
Aug 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Payam NahidAndrew Vernon
Apr 3, 2016·The Lancet Infectious Diseases·Robert S WallisAlimuddin Zumla
Mar 29, 2014·The Lancet Infectious Diseases·Alimuddin I ZumlaAndrew J Nunn
Apr 20, 2012·Expert Review of Anti-infective Therapy·Rannakoe J Lehloenya, Keertan Dheda
May 1, 1984·Anaesthesia·C E Coll
Sep 7, 1986·The International Journal of Health Planning and Management·R Schulz, R Harrison
Aug 8, 2012·Antimicrobial Agents and Chemotherapy·Kwok-Chiu ChangYing Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.